CEO & FounderFounder and CEO of Grafa, leading the company's vision to democratise financial data and empower investors with innovative tools.
The Singapore International Commercial Court has dismissed in full the Republic of Poland’s application to set aside an Energy Charter Treaty arbitration award in favour of GreenX Metals (ASX:GRX).
Imricor Medical Systems (ASX:IMR) announced that the US Food and Drug Administration has granted 510(k) clearance for its Vision-MR Diagnostic Catheter.
Coda Minerals (ASX:COD) has resumed its major drilling program at the Elizabeth Creek Copper-Silver Project in South Australia following the holiday break.
Findi (ASX:FND) has announced that its Indian subsidiary, Transaction Solutions International (India) Private, has entered into a binding term sheet with Nova Global Opportunities Fund PCC for a strategic investment of up to 4.18 billion Indian rupees.
A hedge fund heavyweight says Bitcoin is heading for a $15 trillion market cap and an eight-times surge.
Western Australia is poised to maintain its position as Australia's fastest-growing state for the next four decades, even as overall population growth slows nationally, according to the 2025 Population Statement.
Hundreds of high-net-worth individuals are increasingly using cryptocurrency to buy residential real estate across Europe as digital assets move closer to mainstream finance.
Delcath Systems (NASDAQ:DCTH), an interventional oncology company specializing in treatments for primary and metastatic liver cancers, announced preliminary unaudited financial results and business updates for the fourth quarter and full year ended December 31, 2025.
Cartesian Therapeutics (NASDAQ:RNAC) provided an update on its Descartes-08 program, a first-in-class autologous mRNA-engineered CAR-T cell therapy targeting B-cell maturation antigen (BCMA) for the treatment of autoimmune diseases, and outlined key 2026 priorities.
Perspective Therapeutics (NYSE:CATX) reported updated interim safety and efficacy data from its ongoing Phase 1/2a trial of [212Pb]VMT-α-NET, a targeted alpha-particle radiopharmaceutical for the treatment of neuroendocrine tumors, with a data cut-off of December 10, 2025.
